The Cigna Group (CI)
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Cigna: Flashing A Buy For Dividend Growth And Deep Value
Cigna Group remains a Buy, with catalysts for double-digit adjusted income per share growth resuming in 2027 and beyond. CI's pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks drive both topline and margin growth. Shares trade at an 8.5x forward P/E, a 29% discount to fair value, supporting a projected 17% annual total return through 2031.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.
California Public Employees Retirement System Lowers Stock Position in Cigna Group $CI
California Public Employees Retirement System trimmed its position in Cigna Group (NYSE: CI) by 9.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 690,200 shares of the health services provider's stock after selling 67,990 shares during the quarter. California Public
Ameriprise Financial Inc. Purchases 753,865 Shares of Cigna Group $CI
Ameriprise Financial Inc. boosted its position in Cigna Group (NYSE: CI) by 54.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,136,311 shares of the health services provider's stock after acquiring an additional 753,865 shares during the period. Ameriprise
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.
CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
CVS Health (NYSE: CVS) and Cigna Group (NYSE: CI) are both major players in American healthcare.
4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage
The Medical-HMO industry leverages technology capabilities and M&A to fuel growth. Yet rising medical costs, workforce shortages and policy shifts pose roadblocks.
Cigna: Repeated Earnings Beats, But The Market Remains Skeptical
Cigna delivered another quarter of strong revenue and EPS beats, yet remains deeply discounted versus sector peers. CI's Evernorth Health Services segment drove 17% Q4 revenue growth, while aggressive buybacks and disciplined cost control supported EPS and margins. Management's conservative 2026 guidance appears intentionally low; I expect actual results to exceed both company and consensus forecasts.
